Pramlintide, the Synthetic Analogue of Amylin: Physiology, Pathophysiology, and Effects on Glycemic Control, Body Weight, and Selected Biomarkers of Vascular Risk

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2008 Jun 20

PMID 18561511

Citations 25

Authors

Byron J Hoogwerf

Krupa B Doshi

Dima Diab

Affiliations

Soon will be listed here.

Abstract

Pramlintide is a synthetic version of the naturally occurring pancreatic peptide called amylin. Amylin and pramlintide have similar effects on lowering postprandial glucose, lowering postprandial glucagon and delaying gastric emptying. Pramlintide use in type 1 and insulin requiring type 2 diabetes mellitus (DM) is associated with modest reductions in HbAlc often accompanied by weight loss. Limited data show a neutral effect on blood pressure. Small studies suggest small reductions in LDL-cholesterol in type 2 DM and modest reductions in triglycerides in type 1 DM. Markers of oxidation are also reduced in conjunction with reductions in postprandial glucose. Nausea is the most common side effect. These data indicate that pramlintide has a role in glycemic control of both type 1 and type 2 DM. Pramlintide use is associated with favorable effects on weight, lipids and other biomarkers for atherosclerotic disease.

Citing Articles

Mitigating diabetes associated with reactive oxygen species (ROS) and protein aggregation through pharmacological interventions.

Bennici G, Almahasheer H, Alghrably M, Valensin D, Kola A, Kokotidou C RSC Adv. 2024; 14(25):17448-17460.

PMID: 38813124 PMC: 11135279. DOI: 10.1039/d4ra02349h.

Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.

Erzen S, Tonin G, Jurisic Erzen D, Klen J Int J Mol Sci. 2024; 25(3).

PMID: 38338796 PMC: 10855385. DOI: 10.3390/ijms25031517.

Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine.

Medak K, Jeromson S, Bellucci A, Arbeau M, Wright D iScience. 2024; 27(1):108628.

PMID: 38188526 PMC: 10767228. DOI: 10.1016/j.isci.2023.108628.

Pharmacotherapy for chronic obesity management: a look into the future.

Abdel-Malek M, Yang L, Miras A Intern Emerg Med. 2023; 18(4):1019-1030.

PMID: 37249754 PMC: 10326094. DOI: 10.1007/s11739-023-03237-4.

The endocrine pancreas during exercise in people with and without type 1 diabetes: Beyond the beta-cell.

McCarthy O, Schmidt S, Christensen M, Bain S, Norgaard K, Bracken R Front Endocrinol (Lausanne). 2022; 13:981723.

PMID: 36147573 PMC: 9485437. DOI: 10.3389/fendo.2022.981723.

References

Kolterman O, Schwartz S, Corder C, Levy B, Klaff L, Peterson J . Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996; 39(4):492-9. DOI: 10.1007/BF00400683. View

Fineman M, Koda J, Shen L, Strobel S, Maggs D, Weyer C . The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002; 51(5):636-41. DOI: 10.1053/meta.2002.32022. View

Hollander P, Levy P, Fineman M, Maggs D, Shen L, Strobel S . Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003; 26(3):784-90. DOI: 10.2337/diacare.26.3.784. View

Vella A, Lee J, Camilleri M, Szarka L, Burton D, Zinsmeister A . Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil. 2002; 14(2):123-31. DOI: 10.1046/j.1365-2982.2002.00311.x. View

Shishehbor M, Aviles R, Brennan M, Fu X, Goormastic M, Pearce G . Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003; 289(13):1675-80. DOI: 10.1001/jama.289.13.1675. View

Ratner R, Whitehouse F, Fineman M, Strobel S, Shen L, Maggs D . Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 2005; 113(4):199-204. DOI: 10.1055/s-2005-837662. View

Hoogwerf B . Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. Cleve Clin J Med. 2006; 73(5):477-84. DOI: 10.3949/ccjm.73.5.477. View

Marrero D, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K . Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007; 30(2):210-6. DOI: 10.2337/dc06-1026. View

Kong M, Stubbs T, King P, MacDonald I, Lambourne J, Blackshaw P . The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998; 41(5):577-83. DOI: 10.1007/s001250050949. View

10.

Purnell J, Weyer C . Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol. 2005; 2(1):33-47. DOI: 10.2165/00024677-200302010-00004. View

11.

Young A . Tissue expression and secretion of amylin. Adv Pharmacol. 2006; 52:19-45. DOI: 10.1016/S1054-3589(05)52002-7. View

12.

Ratner R, Dickey R, Fineman M, Maggs D, Shen L, Strobel S . Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004; 21(11):1204-12. DOI: 10.1111/j.1464-5491.2004.01319.x. View

13.

Nicholls S, Hazen S . Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005; 25(6):1102-11. DOI: 10.1161/01.ATV.0000163262.83456.6d. View

14.

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

15.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

16.

Kailasam M, Parmer R, Tyrell E, Henry R, OConnor D . Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens. 2000; 18(11):1611-20. DOI: 10.1097/00004872-200018110-00012. View

17.

Baron A, Kim D, Weyer C . Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord. 2002; 2(1):63-82. View

18.

Weyer C, Fineman M, Strobel S, Shen L, Data J, Kolterman O . Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005; 62(8):816-22. DOI: 10.1093/ajhp/62.8.816. View

19.

Shah P, Vella A, Basu A, Basu R, Schwenk W, Rizza R . Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000; 85(11):4053-9. DOI: 10.1210/jcem.85.11.6993. View

20.

Uwaifo G, Ratner R . Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am. 2005; 34(1):155-97. DOI: 10.1016/j.ecl.2004.11.006. View